The Uromigos

Broadcasting the latest developments in GU cancer Hosted by Brian Rini and Tom Powles Brian Rini MD is an Ingram Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Center Tom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London

496 episodi

Episode 530: ESMO 2026 Review
2/11/2026
1:00:29
Silke, Brian and Tom review exciting ESMO 2026 data in GU Oncology and more.
Episode 529: ESMO 2026 - LITESPARK-011 Updated Results including Overall Survival
25/10/2026
30:34
Danny Heng joins the show to discuss his ESMO 2026 presentation of LITESPARK-011 and the OS data. Published today in Annals of Oncology!
Non perdere nemmeno un episodio di “The Uromigos”. Iscriviti all'app gratuita GetPodcast.
Episode 528: ESMO 2026 - LITESPARK 012
25/10/2026
44:02
Martin Voss takes on the role of Host and interviews Brian and Tom about this phase 3 study of triplets in metastatic ccRCC. Published today in Annals of Oncology!
Episode 527: ESMO 2026 - DASL-HiCaP Adding Darolutamide to ADT and XRT in High-risk Localized Prostate Cancer
24/10/2026
38:18
Chris Sweeney discusses this ANZUP trial which adds more phase 3 data to the high risk prostate cancer space.
Episode 526: ESMO 2026 - The VOLGA trial in MIBC
24/10/2026
37:07
Michiel Van Der Heijden joins us after his ESMO discussion and Tom's presentation to discuss how these critical data reshape the MIBC landscape.
Episode 525: ESMO 2026 - PEACE-1 and CAPItello-281
24/10/2026
46:49
Karim Fizazi joins Brian and Tom to discuss two ESMO 2026 presentations of long-term follow up data in mHSPC
Episode 524: ESMO 2026 - JNJ-6143, a Novel RIPTAC in mCRPC
24/10/2026
16:09
Ben Garmezy discusses the phase 1 data of a novel mechanism in CRPC. This RIPTAC (Regulated Induced Proximity TargetingChimera) Molecule uses AR to enter the prostate cancer cell and inhibits BRD4 to interfere with cell transcription.
Episode 523: ESMO 2026: ctDNA Kinetics from Neoadjuvant EVP in MIBC
23/10/2026
35:33
Jon Chatzkel joins us after his ESMO 2026 presentation to discuss ctDNA results from the KEYNOTE 905 trial.
Episode 522: ESMO 2026 - KEYNOTE-905 Analysis of Neoadjuvant EVP or Pembro Monotherapy in Cis-ineligible MIBC
23/10/2026
24:24
Anders Ullen joins the show after his EMSO 2026 presentation looking at KN-905 for the period in which Cis-ineligible MIBC patients were randomized to immediate cystectomy vs neoadjuvant Pembro or EVP.
Episode 521: ESMO 2026 - Reconciling Discrepant Results of Neoadjuvant Chemotherapy + IO in MIBC
23/10/2026
32:47
Rob Jones joins the show to discuss two phase 3 trials from ESMO 2026 which did not show benefit from chemotherapy + IO vs chemo in MIBC. We discuss the wider implications incorporating the NIAGARA data and in light of neo/adjuvant EVP.

Altri episodi

Accedi a tutto il mondo dei podcast con l’app gratuita GetPodcast.

Iscriviti ai tuoi podcast preferiti, ascolta gli episodi offline e ricevi fantastici consigli.

Un'azienda di

The Uromigos

The Uromigos

496 episodi

Episode 530: ESMO 2026 Review

Episode 529: ESMO 2026 - LITESPARK-011 Updated Results including Overall Survival

Episode 528: ESMO 2026 - LITESPARK 012

Episode 527: ESMO 2026 - DASL-HiCaP Adding Darolutamide to ADT and XRT in High-risk Localized Prostate Cancer

Episode 526: ESMO 2026 - The VOLGA trial in MIBC

Episode 525: ESMO 2026 - PEACE-1 and CAPItello-281

Episode 524: ESMO 2026 - JNJ-6143, a Novel RIPTAC in mCRPC

Episode 523: ESMO 2026: ctDNA Kinetics from Neoadjuvant EVP in MIBC

Episode 522: ESMO 2026 - KEYNOTE-905 Analysis of Neoadjuvant EVP or Pembro Monotherapy in Cis-ineligible MIBC

Episode 521: ESMO 2026 - Reconciling Discrepant Results of Neoadjuvant Chemotherapy + IO in MIBC